Objective:To systematically evaluate the prevalence of dysphagia after treatment in patients with head and neck cancer.Methods:The Wanfang, CNKI, Web of Science, Embase, and PubMed databases were searched from their inception to May 2025. Two researchers independently performed literature screening, data extraction, and risk of bias assessment. The pooled prevalence and 95% confidence interval (CI) were used as effect measures, with heterogeneity assessed using the I2 statistics. Sensitivity analysis was conducted by a leave-one-out approach, and publication bias was evaluated using Egger's test and funnel plots. Results:A total of 18 studies were included, comprising 2,518 patients with head and neck cancer, of whom 1,303 were diagnosed with dysphagia. The meta-analysis showed that the overall prevalence of dysphagia after treatment was 51.2% (95% CI: 42.2%-60.2%). Subgroup analysis indicated higher prevalence among males (49.8%, 95% CI: 35.6%-64.0%), Asian populations (57.7%, 95% CI: 36.8%-77.2%), tumors of the hypopharynx and larynx (45.7%, 95% CI: 39.3%-52.2%), stage Ⅲ-Ⅳ disease (46.3%, 95% CI: 34.9%-58.0%), patients receiving concurrent chemoradiotherapy (51.0%, 95% CI: 41.5%-60.4%), smokers (53.0%, 95% CI: 35.1%-70.6%), studies published in 2020 or earlier (51.9%, 95% CI: 38.3%-65.4%), high-quality studies (66.5%, 95% CI: 45.1%-84.9%), and patients with a post-treatment interval ≤6 months (60.7%, 95% CI: 41.8%-78.1%) (all P<0.001). Conclusions:The prevalence of dysphagia after treatment in patients with head and neck cancer is high, with significant variations related to gender, tumor site, disease stage, geographic region, treatment modality, smoking status, publication year, study quality, and post-treatment interval. Early screening and timely intervention are recommended to improve the quality of life of patients with head and neck cancer.

Objective:To systematically evaluate the prevalence of dysphagia after treatment in patients with head and neck cancer.Methods:The Wanfang, CNKI, Web of Science, Embase, and PubMed databases were searched from their inception to May 2025. Two researchers independently performed literature screening, data extraction, and risk of bias assessment. The pooled prevalence and 95% confidence interval (CI) were used as effect measures, with heterogeneity assessed using the I2 statistics. Sensitivity analysis was conducted by a leave-one-out approach, and publication bias was evaluated using Egger's test and funnel plots. Results:A total of 18 studies were included, comprising 2,518 patients with head and neck cancer, of whom 1,303 were diagnosed with dysphagia. The meta-analysis showed that the overall prevalence of dysphagia after treatment was 51.2% (95% CI: 42.2%-60.2%). Subgroup analysis indicated higher prevalence among males (49.8%, 95% CI: 35.6%-64.0%), Asian populations (57.7%, 95% CI: 36.8%-77.2%), tumors of the hypopharynx and larynx (45.7%, 95% CI: 39.3%-52.2%), stage Ⅲ-Ⅳ disease (46.3%, 95% CI: 34.9%-58.0%), patients receiving concurrent chemoradiotherapy (51.0%, 95% CI: 41.5%-60.4%), smokers (53.0%, 95% CI: 35.1%-70.6%), studies published in 2020 or earlier (51.9%, 95% CI: 38.3%-65.4%), high-quality studies (66.5%, 95% CI: 45.1%-84.9%), and patients with a post-treatment interval ≤6 months (60.7%, 95% CI: 41.8%-78.1%) (all P<0.001). Conclusions:The prevalence of dysphagia after treatment in patients with head and neck cancer is high, with significant variations related to gender, tumor site, disease stage, geographic region, treatment modality, smoking status, publication year, study quality, and post-treatment interval. Early screening and timely intervention are recommended to improve the quality of life of patients with head and neck cancer.

Objective:To describe our experiences in application of the 2019 revision of "CCCG-WT-2016" for the diagnosis of Wilms tumors.Methods:Ninety-one cases of Wilms tumor diagnosed at Shanghai Children′s Medical Center from January 2015 to December 2018 were collected. All cases were reviewed by two senior pathologists, including one from China and the other from Singapore, according to the 2019 revision of "CCCG-WT-2016."Results:The specimens were obtained by core biopsy ( n=21), primary nephrectomy ( n=41), post-chemotherapy nephrectomy/resection ( n=18), or biopsy/resection of metastatic/relapse/post-chemotherapy metastatic lesion(s) ( n=11). The specimens of core biopsy and primary nephrectomy ( n=62) all had favorable histology.Twelve post-chemotherapy nephrectomy cases were subdivided into three risk groups: low risk ( n=0), intermediate risk ( n=10) and high risk ( n=2). Six post-chemotherapy resection cases were subdivided into 3 risk groups:low risk ( n=0), intermediate risk ( n=5) and high risk ( n=1). The remaining 11 cases were comprised of metastatic, relapse, and post-chemotherapy metastatic lesions. The concordance rate of the two senior pathologists was 100%(91/91). Conclusions:The 2019 revision of "CCCG-WT-2016" is clearly written and easy to use. It can serve as the basis of accurate classification for clinical treatment.